Orrick Advises Vitruvian Partners on Darktrace’s $50 Million Series E

Orrick has advised European private equity firm Vitruvian Partners as the lead investor in Darktrace’s $50 million Series E financing round at a pre-money valuation of $1.6 billion. A U.K.-based cyber defense firm, Darktrace’s technology is modeled on the human immune system and is the world’s leading, enterprise-grade AI with over 7,000 deployments worldwide. Existing investors Kohlberg Kravis Roberts and TenEleven Ventures also participated in the round.

Over the past year, Orrick has advised Vitruvian on a number of investments, including in Smava, BitDefender and Carwow, as well as a selling shareholder in Farfetch’s $5.8 billion initial public offering. The Orrick team was led by partner Ylan Steiner and included associates Alex Gest, Michael Gale, Charles Baker and Candice O’Brien.